Oncology Biomarkers

Post-hoc analysis shows potential of biomarkers for identifying pancreatic patients who respond to treatment.

Pfizer’s sigvotatug vedotin combined with Keytruda is being studied in patients with non-small cell lung cancer. Researchers suggest sigvotatug vedotin’s ability to induce immunogenic cell death may enhance antitumor activity.

A Brazilian study shows a correlation between circulating tumor cell and overall survival in a trial assessing a treatment of gastric cancer.

The data further identify ctDNA as a dependable biomarker for assessing response to bispecific antibody treatment

An analysis of patients with stage III colon patients found celecoxib improves survival only in those who are positive for circulating tumor DNA.

By identifying the isoforms of the prostate-specific antigen (PSA), the new test may distinguish between prostate cancer and other causes of elevated PSA levels.

High levels of integrin beta-6 (IB6) in metastatic non-small cell lung cancer suggest that it could be a target for treatment.

New research highlights DR-70 as a promising noninvasive biomarker for diagnosing and staging bladder cancer, potentially improving early detection strategies.

A study reveals circulating tumor cells (CTCs) as potential biomarkers for predicting aggressive DCIS, aiming to reduce overtreatment and improve patient outcomes.

Next-generation sequencing (NGS) holds great promise for identifying 'tumor-agnostic' therapies, but evidence does not support its routine use in clinical care and diagnosis of sarcoma, a consensus statement concludes.

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent research focuses on the ‘omics’ technologies —genomics, proteomics, metabolomics.

Promoting interdisciplinary collaboration via molecular tumor boards and shared decision-making frameworks might improve the precision and applicability of testing in clinical settings, according to a set of new Academy of Managed Care Pharmacy recommendations.

Many potential colorectal biomarkers are only studied once.